Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)

Autor: Eleonor Rivin del Campo, J. M. A. Northover, Laurence Collette, Melissa Christiaens, Kathryn Winter, Helen Meadows, Jaffer A. Ajani, Jean François Bosset, Marc Puyraveau, Didier Peiffert, Philippe Maingon, A. Bapsi Chakravarthy, Rob Glynne-Jones, Jean Michel Hannoun-Levi, Oscar Matzinger, Karin Haustermans, Andre Konski
Přispěvatelé: Service d'oncologie-radiothérapie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU), University Hospitals Leuven [Leuven], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Perelman School of Medicine, University of Pennsylvania [Philadelphia], MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Service d'Oncologie Radiothérapie [CHU Pitié Salpétrière], CHU Pitié-Salpêtrière [AP-HP]
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Cancer Research
MODULATED RADIATION-THERAPY
medicine.medical_treatment
LOCAL-CONTROL
CHEMORADIATION
0302 clinical medicine
Radiation
HIGH-DOSE RADIATION
Radiotherapy Dosage
Chemoradiotherapy
Anus Neoplasms
Combined Modality Therapy
3. Good health
Pooled analysis
Treatment Outcome
Chemoradiation
030220 oncology & carcinogenesis
5-FLUOROURACIL
SQUAMOUS-CELL CARCINOMA
Fluorouracil
Life Sciences & Biomedicine
Overall treatment time
medicine.medical_specialty
Mitomycin
MITOMYCIN-C
[SDV.CAN]Life Sciences [q-bio]/Cancer
[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine
Article
03 medical and health sciences
Clinical Trials
Phase II as Topic
TREATMENT TIME
Internal medicine
medicine
CANAL CARCINOMA
Anal cancer
Humans
External beam radiotherapy
Progression-free survival
Science & Technology
business.industry
Proportional hazards model
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
medicine.disease
Confidence interval
Radiation therapy
030104 developmental biology
Clinical Trials
Phase III as Topic
Concomitant
Neoplasm Recurrence
Local
FOLLOW-UP
business
Zdroj: Eur J Cancer
European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 121, pp.130-143. ⟨10.1016/j.ejca.2019.08.022⟩
ISSN: 1879-0852
0959-8049
Popis: PURPOSE: Concomitant external-beam radiochemotherapy (5-fluorouracil-mitomycin C) has become the standard of care in anal cancer since the '90s. A pooled analysis of individual patient data from 7 major trials was performed quantifying the effect of radiation therapy (RT)-related parameters on the outcome of patients with anal cancer. MATERIALS AND METHODS: Pooling databases from combined modality trials, the impact of RT parameters (total dose, gap duration, OTT: overall treatment time) on outcome including locoregional failure (LRF), 5-year progression free survival (PFS) and toxicities were investigated. Individual patient data were received for 10/13 identified published studies conducted from 1987 to 2008 (n = 3031). A Cox regression model was used (landmark = 3 months after RT for first follow-up). RESULTS: After data inspection indicating severe heterogeneity between trials, only 1343 patients from 7/10 studies received were analysed (the most recent ones, since 1994; median follow-up = 4.1 years). A higher overall 5-year LRF rate [22.8% (95% confidence interval [CI] 22.3-27.3%)] significantly correlated with longer OTT (p = 0.03), larger tumour size (p
Databáze: OpenAIRE
Externí odkaz: